ELYRADIA BIOTECHNOLOGY LIMITED – Trademark Portfolio
Entity Type: 24
ELYRADIA BIOTECHNOLOGY LIMITED holds 13 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 10 (Medical Apparatus) — 8 filings in this category. The portfolio also extends into Class 5 (Pharmaceuticals) across 3 Nice Classification classes. Currently, 12 trademarks are registered. Notable registered marks include WTTOD, AOGSKY, CHYHOO, DEMHOO, and LORSKI. The owner is based in BRIGHTON.
37 WELLINGTON ROAD
BRIGHTON BN2 3AB , GB
Showing of trademarks Trademarks
Trademark Classifications
ELYRADIA BIOTECHNOLOGY LIMITED's trademark portfolio spans 3 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes
Industrial oils and greases; lubricants; dust absorbing, wetting and binding compositions
Frequently Asked Questions
How many trademarks does ELYRADIA BIOTECHNOLOGY LIMITED have?
ELYRADIA BIOTECHNOLOGY LIMITED has 13 U.S. trademarks filed with the USPTO. Of these, 12 registered, 1 cancelled.
What trademark classes does ELYRADIA BIOTECHNOLOGY LIMITED file in?
ELYRADIA BIOTECHNOLOGY LIMITED files trademarks across 3 Nice Classification classes. The most active classes are Class 10 (Medical Apparatus), Class 5 (Pharmaceuticals), Class 4 (Lubricants & Fuels). Class 10 covers surgical, medical, dental and veterinary apparatus and instruments.
What are ELYRADIA BIOTECHNOLOGY LIMITED's most well-known trademarks?
ELYRADIA BIOTECHNOLOGY LIMITED's registered trademark portfolio includes well-known marks such as WTTOD, AOGSKY, CHYHOO, DEMHOO, and LORSKI. These are among 12 currently registered trademarks in the portfolio.
What is ELYRADIA BIOTECHNOLOGY LIMITED's trademark registration success rate?
ELYRADIA BIOTECHNOLOGY LIMITED has a 92% trademark registration rate, with 12 out of 13 resolved applications resulting in successful registration. Currently, 0 applications are pending review.